Bedford recalls Vecuronium Bromide for Injection at hospital/user-level
Bedford Laboratories has issued hospital/user-level voluntarily recall of Vecuronium Bromide for Injection preservative free, Lot 2067134, because of possible health risk.
The voluntary recall is being conducted due to the discovery of particulate matter, which has been recognized as a potential health hazard, in a small number of vials within the lot.
The adverse reactions due to particulate matter may include vein irritation and phlebitis, clinically occult pulmonary granulomas detected at routine autopsy examination, local tissue infarction, pulmonary dysfunction, occlusion of capillaries and arteries, anaphylactic shock and death.
Vecuronium Bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs